Similarly, no objective responses were seen in locally advanced or metastatic pancreatic cancer patients treated with cytotoxic T-lymphocyte associated protein 4 (CTLA-4) inhibitor monotherapy [9]. The gene discussed is CTLA4; the disease is familial pancreatic carcinoma.